| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation
|
Yamamoto, Chihiro
|
|
|
3 |
21 |
p. 3266-3277
|
artikel
|
| 2 |
Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus
|
Badawy, Sherif M.
|
|
|
3 |
21 |
p. 3297-3306
|
artikel
|
| 3 |
Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans
|
Masselink, Leah E.
|
|
|
3 |
21 |
p. 3278-3286
|
artikel
|
| 4 |
Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome
|
Mason, Emily F.
|
|
|
3 |
21 |
p. 3322-3332
|
artikel
|
| 5 |
Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation
|
Iliopoulou, Bettina P.
|
|
|
3 |
21 |
p. 3419-3431
|
artikel
|
| 6 |
CAR T-cell therapy: is it prime time in myeloma?
|
Sidana, Surbhi
|
|
|
3 |
21 |
p. 3473-3480
|
artikel
|
| 7 |
Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells
|
Bystrom, Laura M.
|
|
|
3 |
21 |
p. 3261-3265
|
artikel
|
| 8 |
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
|
Thol, Felicitas
|
|
|
3 |
21 |
p. 3449-3453
|
artikel
|
| 9 |
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
|
Sanz, Guillermo F.
|
|
|
3 |
21 |
p. 3454-3460
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
3 |
21 |
p. i
|
artikel
|
| 11 |
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
|
Von Drygalski, Annette
|
|
|
3 |
21 |
p. 3241-3247
|
artikel
|
| 12 |
Genome editing of HBG1 and HBG2 to induce fetal hemoglobin
|
Métais, Jean-Yves
|
|
|
3 |
21 |
p. 3379-3392
|
artikel
|
| 13 |
Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities
|
Cardin, Sophie
|
|
|
3 |
21 |
p. 3307-3321
|
artikel
|
| 14 |
Human MYD88 L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
|
Sewastianik, Tomasz
|
|
|
3 |
21 |
p. 3360-3374
|
artikel
|
| 15 |
Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis
|
Arruda, Lucas C.M.
|
|
|
3 |
21 |
p. 3436-3448
|
artikel
|
| 16 |
Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT
|
Akahoshi, Yu
|
|
|
3 |
21 |
p. 3287-3296
|
artikel
|
| 17 |
Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion
|
Umezu, Tomohiro
|
|
|
3 |
21 |
p. 3228-3240
|
artikel
|
| 18 |
Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma
|
Lin, Yu-Hsiu T.
|
|
|
3 |
21 |
p. 3214-3227
|
artikel
|
| 19 |
Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia
|
Alsawah, Fares
|
|
|
3 |
21 |
p. 3333-3336
|
artikel
|
| 20 |
Large-scale in vitro production of red blood cells from human peripheral blood mononuclear cells
|
Heshusius, Steven
|
|
|
3 |
21 |
p. 3337-3350
|
artikel
|
| 21 |
Microbiota modification in hematology: still at the bench or ready for the bedside?
|
Severyn, Christopher J.
|
|
|
3 |
21 |
p. 3461-3472
|
artikel
|
| 22 |
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
|
Bader, Peter
|
|
|
3 |
21 |
p. 3393-3405
|
artikel
|
| 23 |
New therapies for von Willebrand disease
|
Mannucci, Pier Mannuccio
|
|
|
3 |
21 |
p. 3481-3487
|
artikel
|
| 24 |
Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
|
Huang, Qiu-Sha
|
|
|
3 |
21 |
p. 3406-3418
|
artikel
|
| 25 |
Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome
|
Fujimura, Yoshihiro
|
|
|
3 |
21 |
p. 3191-3195
|
artikel
|
| 26 |
Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation
|
Kwon, Mi
|
|
|
3 |
21 |
p. 3351-3359
|
artikel
|
| 27 |
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
|
Schmidts, Andrea
|
|
|
3 |
21 |
p. 3248-3260
|
artikel
|
| 28 |
Replication timing alterations in leukemia affect clinically relevant chromosome domains
|
Rivera-Mulia, Juan Carlos
|
|
|
3 |
21 |
p. 3201-3213
|
artikel
|
| 29 |
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
|
Maffioli, Margherita
|
|
|
3 |
21 |
p. 3196-3200
|
artikel
|
| 30 |
Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model
|
Richartz, Nina
|
|
|
3 |
21 |
p. 3181-3190
|
artikel
|
| 31 |
Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil
|
Fioredda, F.
|
|
|
3 |
21 |
p. 3432-3435
|
artikel
|
| 32 |
Thrombus stability explains the factor V Leiden paradox: a mouse model
|
Shaya, S.A.
|
|
|
3 |
21 |
p. 3375-3378
|
artikel
|
Tijdschrift beschrijving